To further support this point, two native samples of patients diagnosed with KIT D816V or FLT3 ITD positive AML were treated with crenolanib in dose-dilution assays for 48 hours and reduction of the viable (CD45 low positive) cell cohort was determined flow cytometrically. The gene discussed is PTPRC; the disease is acute myeloid leukemia.